Comparative Pharmacology
Head-to-head clinical analysis: FUNGIZONE versus MICONAZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNGIZONE versus MICONAZOLE 3.
FUNGIZONE vs MICONAZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
For vaginal candidiasis: 200 mg (one suppository) intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
Terminal half-life is approximately 24 hours (range 20-30 hours) following topical vaginal application; prolonged in hepatic impairment.
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Primarily hepatic metabolism; <1% excreted unchanged in urine; fecal elimination accounts for ~50% of metabolites.
Category C
Category A/B
Antifungal
Antifungal